DIVO vs IBB
Amplify CWP Enhanced Dividend Income ETF vs iShares Biotechnology ETF
- • IBB has the lower expense ratio at 0.44% vs 0.56% for DIVO.
- • DIVO pays a higher dividend yield (2.31%).
Side-by-side metrics
| Metric | DIVO | IBB |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.56% | 0.44% |
Dividend yield Trailing 12-month yield. | 2.31% | 0.16% |
AUM Assets under management — bigger funds are typically more liquid. | $8.01B | $11.50B |
YTD return | 10.78% | 30.22% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.53 | 0.60 |
P/E ratio | 22.07 | 25.48 |
Last price | $47.41 | $217.75 |
Inception | — | — |
Issuer | Amplify | iShares |
DIVO top holdings
| MSFT | Microsoft Corp | 5.86% |
| AMGN | Amgen Inc | 5.74% |
| V | Visa Inc Class A | 5.42% |
| AGPXX | Invesco Shrt-Trm Inv Gov&Agcy Instl | 5.34% |
| AAPL | Apple Inc | 5.08% |
| JPM | JPMorgan Chase & Co | 4.94% |
| GS | The Goldman Sachs Group Inc | 4.88% |
| CAT | Caterpillar Inc | 4.51% |
| SOFR | Amplify Samsung SOFR ETF | 4.16% |
| AXP | American Express Co | 4.12% |
IBB top holdings
| GILD | Gilead Sciences Inc | 8.94% |
| AMGN | Amgen Inc | 8.31% |
| VRTX | Vertex Pharmaceuticals Inc | 7.87% |
| REGN | Regeneron Pharmaceuticals Inc | 6.24% |
| MRNA | Moderna Inc | 5.49% |
| NTRA | Natera Inc | 3.78% |
| ARGX | argenx SE ADR | 3.36% |
| BIIB | Biogen Inc | 2.52% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 2.50% |
| ILMN | Illumina Inc | 2.41% |
About DIVO
DIVO (Amplify CWP Enhanced Dividend Income ETF) is Quality dividend payers with tactical covered calls. Managed by Amplify, the fund carries $8.0B in assets under management, an expense ratio of 0.56%, a dividend yield of 2.31%. Its largest holding is Microsoft Corp (MSFT), which represents 5.9% of the portfolio. Consumer Cyclical is the fund's largest sector exposure at 5.4%.
About IBB
IBB (iShares Biotechnology ETF) is NASDAQ biotech and pharmaceutical companies. Managed by iShares, the fund carries $11.5B in assets under management, an expense ratio of 0.44%, a dividend yield of 0.16%. Its largest holding is Gilead Sciences Inc (GILD), which represents 8.9% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.